Literature DB >> 16007491

Evidence of positive Darwinian selection in putative meningococcal vaccine antigens.

David A Fitzpatrick1, Christopher J Creevey, James O McInerney.   

Abstract

Meningococcal meningitidis is a life-threatening disease. In Europe and the United States the majority of cases are caused by virulent meningococcal strains belonging to serogroup B. Presently there is no effective vaccine against serogroup B strains, as traditional vaccine antigens such as polysaccharide capsules are unusable as they lead to autoimmunity. The year 2000 saw the publication of the complete genome of Neisseria meningitidis MC58, a virulent serogroup B bacterium. Working in conjunction with the sequencing project, researchers endeavored to locate highly conserved membrane-associated proteins that elicit an immune response. It is hoped that these proteins will provide a basis for novel vaccines against serogroup B strains. A number of potential vaccine antigens have been located and are presently in phase I clinical trials. Recently many reports pertaining to the evidence of positive Darwinian selection in membrane proteins of pathogens have been reported. This study utilized in silico methods to test for evidence of historical positive Darwinian selection in seven such vaccine candidates. We found that two of these proteins show signatures of adaptive evolution, while the remaining proteins show evidence of strong purifying selection. This has significant implications for the design of a vaccine against serogroup B strains, as it has been shown that vaccines that target epitopes that are under strong purifying selection are better than those that target variable epitopes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007491     DOI: 10.1007/s00239-004-0290-6

Source DB:  PubMed          Journal:  J Mol Evol        ISSN: 0022-2844            Impact factor:   2.395


  41 in total

1.  Codon-substitution models for heterogeneous selection pressure at amino acid sites.

Authors:  Z Yang; R Nielsen; N Goldman; A M Pedersen
Journal:  Genetics       Date:  2000-05       Impact factor: 4.562

2.  Reliabilities of parsimony-based and likelihood-based methods for detecting positive selection at single amino acid sites.

Authors:  Y Suzuki; M Nei
Journal:  Mol Biol Evol       Date:  2001-12       Impact factor: 16.240

3.  Detecting recombination from gene trees.

Authors:  J Maynard Smith; N H Smith
Journal:  Mol Biol Evol       Date:  1998-05       Impact factor: 16.240

4.  Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene.

Authors:  R Nielsen; Z Yang
Journal:  Genetics       Date:  1998-03       Impact factor: 4.562

5.  Genealogical evidence for positive selection in the nef gene of HIV-1.

Authors:  P M Zanotto; E G Kallas; R F de Souza; E C Holmes
Journal:  Genetics       Date:  1999-11       Impact factor: 4.562

6.  Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

Authors:  D Martin; N Cadieux; J Hamel; B R Brodeur
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

7.  Unbiased estimation of the rates of synonymous and nonsynonymous substitution.

Authors:  W H Li
Journal:  J Mol Evol       Date:  1993-01       Impact factor: 2.395

8.  Sequelae one year after meningococcal disease.

Authors:  A Naess; A Halstensen; H Nyland; S H Pedersen; P Møller; R Borgmann; J L Larsen; E Haga
Journal:  Acta Neurol Scand       Date:  1994-02       Impact factor: 3.209

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  7 in total

1.  Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach.

Authors:  Swaine L Chen; Chia-Seui Hung; Jian Xu; Christopher S Reigstad; Vincent Magrini; Aniko Sabo; Darin Blasiar; Tamberlyn Bieri; Rekha R Meyer; Philip Ozersky; Jon R Armstrong; Robert S Fulton; J Phillip Latreille; John Spieth; Thomas M Hooton; Elaine R Mardis; Scott J Hultgren; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

2.  Purifying selection and molecular adaptation in the genome of Verminephrobacter, the heritable symbiotic bacteria of earthworms.

Authors:  Kasper U Kjeldsen; Thomas Bataillon; Nicolás Pinel; Stéphane De Mita; Marie B Lund; Frank Panitz; Christian Bendixen; David A Stahl; Andreas Schramm
Journal:  Genome Biol Evol       Date:  2012-02-14       Impact factor: 3.416

3.  The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution.

Authors:  Andrew McDowell; István Nagy; Márta Magyari; Emma Barnard; Sheila Patrick
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

4.  Genome-Wide Analyses Reveal Genes Subject to Positive Selection in Pasteurella multocida.

Authors:  Peili Cao; Dongchun Guo; Jiasen Liu; Qian Jiang; Zhuofei Xu; Liandong Qu
Journal:  Front Microbiol       Date:  2017-05-30       Impact factor: 5.640

5.  Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach.

Authors:  Isaac Amela; Juan Cedano; Enrique Querol
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

6.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007

7.  Duplicated paralogous genes subject to positive selection in the genome of Trypanosoma brucei.

Authors:  Richard D Emes; Ziheng Yang
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.